Robins Kaplan

Minneapolis-based Robins Kaplan is nationally recommended for its IP group focused on generic Hatch-Waxman litigation. A recent client says the IP team is "thoughtful and methodical in its work on our behalf in a number of high-stakes litigation matters," and "repeatedly demonstrates that our interests are 'top of mind' for them."

Health and life sciences industry group chair Jake Holdreith is focused on pharmaceutical patent litigation for the firm's generic clientele. He was recently involved in numerous matters, including a patent dispute for client Amneal brought by Amgen. A federal judge recently found Amneal did not infringe an asserted patent covering the product Sensipar.

Ronald Schutz is a notable litigator at the firm, and currently serves as chair of the executive board. He recently acted for Puget Bioventures in multiple patent infringement suits involving knee replacement technology. One of the cases against Biomet was resolved last year.